Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572230 | 1.00 | MAPT (0.70) | MAPTMAPK1TDP1MAOAMAOB | |
| SCHEMBL72477 | 1.00 | MAPT (0.70) | MAPTMAPK1TDP1MAOAMAOB | |
| SCHEMBL31039664 | 1.00 | MAPT (0.70) | MAPTMAPK1TDP1MAOAMAOB | |
| SCHEMBL19999732 | 1.00 | MAPT (0.70) | MAPTMAPK1TDP1MAOAMAOB | |
| SCHEMBL12912390 | 1.00 | MAPT (0.70) | MAPTMAPK1TDP1MAOAMAOB | |
| Homopterocarpin SCHEMBL31237481 | 0.92 | MAPT (0.80) | MAPTMAPK1TDP1MAOAMAOB | |
| Homopterocarpin SCHEMBL12998414 | 0.92 | MAPT (0.80) | MAPTMAPK1TDP1MAOAMAOB | |
| Homopterocarpin SCHEMBL29366996 | 0.92 | MAPT (0.80) | MAPTMAPK1TDP1MAOAMAOB | |
| Homopterocarpin SCHEMBL12810250 | 0.92 | MAPT (0.80) | MAPTMAPK1TDP1MAOAMAOB | |
| Homopterocarpin SCHEMBL12810803 | 0.92 | MAPT (0.80) | MAPTMAPK1TDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| US-20240390504-A1 | MULTIFUNCTIONAL CONJUGATES | E P O S IASIS RES AND DEVELOPMENT LIMITED (CY) | 2024-11-28 | — | — | US | claimed |
| CN-118792272-A | Licorice isopentenyl transferase and application thereof | 中国科学院华南植物园 | 2024-10-18 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| US-20230027148-A1 | MULTIFUNCTIONAL CONJUGATES | E.P.O.S IASIS RESEARCH AND DEVELOPMENT LIMITED (CY) | 2023-01-26 | — | — | US | claimed |
| US-11560342-B2 | Bacillus isolates and uses thereof | MONSANTO TECHNOLOGY, LLC (US) | 2023-01-24 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| CN-102241685-B | Method for separating monomer compounds from astragaloside for injection | SICHUAN KELUN PHARMACEUTICAL | 2013-11-06 | — | — | CN | claimed |
| WO-2013044061-A1 | PLANT VIRAL VACCINES AND THERAPEUTICS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-28 | — | — | WO | claimed |
| CN-102241685-A | Method for separating monomer compounds from astragaloside for injection | SICHUAN KELUN PHARMACEUTICAL | 2011-11-16 | — | — | CN | claimed |
| EP-2295031-A2 | Use of pterocarpans as anti-cellulite agents | Symrise AG (DE) | 2011-03-16 | — | — | EP | claimed |
| US-20110034486-A1 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS | SYMRISE GMBH & CO., KG (DE) | 2011-02-10 | — | — | US | claimed |
| US-20100319084-A1 | METABOLIC ENGINEERING FOR PLANT DISEASE RESISTANCE | THE SAMUEL ROBERTS NOBLE FOUNDATION | 2010-12-16 | — | — | US | claimed |
| US-20090208432-A1 | AH Receptor Antagonists | SYMRISE GMBH & CO., KG (DE) | 2009-08-20 | — | — | US | claimed |
| EP-2035430-A1 | 6H-BENZOFURO[3,2-C][1]BENZOPYRAN AND [2]BENZOPYRANO [4,3-B][1]BENZOPYRAN DERIVATIVES AND WOOD EXTRACTS OF THESE COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) ANTAGONISTS FOR THE PREVENTION OF UV-B INDUCED SKIN DAMAGE | Symrise GmbH & Co. KG (DE) | 2009-03-18 | — | — | EP | claimed |
| WO-2007128725-A1 | 6H-BENZOFURO[3,2-C] [1]BENZOPYRAN AND [2] BENZOPYRANO [4,3-B] [1]BENZOPYRAN DERIVATIVES AND WOOD EXTRACTS OF THESE COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) ANTAGONISTS FOR THE PREVENTION OF UV-B INDUCED SKIN DAMAGE | SYMRISE GMBH & CO. KG (DE) | 2007-11-15 | — | — | WO | claimed |
| US-4704400-A | INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK & CO., INC. (US) | 1987-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208432-A1 | AH Receptor Antagonists | AHR, ARNT, HCAR1 | MAPT 4785/4885MAPK1 4118/4885TDP1 4418/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | MAPT 3926/4885MAPK1 3646/4885TDP1 3469/4885 |
| US-20230027148-A1 | MULTIFUNCTIONAL CONJUGATES | MKI67, ACP3, CD44 | MAPT 3085/4885MAPK1 1828/4885TDP1 4283/4885 |
| US-11560342-B2 | Bacillus isolates and uses thereof | BLVRB, BROX, GLB1 | MAPT 738/4885MAPK1 3187/4885TDP1 2471/4885 |
| US-20240390504-A1 | MULTIFUNCTIONAL CONJUGATES | MKI67, ACP3, CD44 | MAPT 3085/4885MAPK1 1828/4885TDP1 4283/4885 |
| US-20110034486-A1 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS | FABP4, PLIN1, CPT1B | MAPT 4747/4885MAPK1 767/4885TDP1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.